Ascendia

  MARKET NEWS

Owen Mumford Wins Distinction in Red Dot Award (Product Design 2023) for AIDAPTUS® Autoinjector
United States Patent & Trademark Office Grants Evoke Pharma a Formulation Patent Covering GIMOTI
Sana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform & Advancements With its In Vivo Fusogen Platform
Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology
Longeveron Announces First Patient Dosed in Phase 2 Clinical Trial for Aging-Related Frailty in Japan
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety & PTSD Stress-Related Disorders

  FEATURED EDITORIAL

  COMPANY PROFILE

As a world-leading drug delivery device solutions provider, Nemera’s goal of putting patients first enables it to design and manufacture devices that maximize treatment efficacy. Nemera is a holistic partner and helps its customers succeed in the sprint to market with its combination products. From early device strategy to state-of-the-art manufacturing, Nemera is committed to the highest quality standards. Agile and open-minded, the company works with its customers as colleagues. Together, they go the extra mile to fulfil its mission. Click here for more.

Featured Video (Click Image)

  EXCLUSIVE ONLINE CONTENT

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 Trial Evaluating Obicetrapib in Patients With Heterozygous Familial Hypercholesterolemia

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 Trial Evaluating Obicetrapib in Patients With Heterozygous Familial Hypercholesterolemia

NewAmsterdam Pharma Company N.V. announced the completion of patient enrollment in the pivotal Phase 3 BROOKYLN clinical trial evaluating obicetrapib in adult patients with heterozygous familial hypercholesterolemia….

Merck Strengthens Immunology Pipeline With Acquisition of Prometheus Biosciences

Merck Strengthens Immunology Pipeline With Acquisition of Prometheus Biosciences

Merck and Prometheus Biosciences, Inc. recently announced the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for….

Clearmind Medicine Engages Experienced CRO to Support its First-in-Human Clinical Trial

Clearmind Medicine Engages Experienced CRO to Support its First-in-Human Clinical Trial

Clearmind Medicine Inc. recently announced additional preparations to facilitate the commencement of the company’s clinical trial and engaged a contract research organization (CRO) to provide support for….

Ajinomoto Bio-Pharma Services Receives FDA Approval for High Potency Fill Line

Ajinomoto Bio-Pharma Services Receives FDA Approval for High Potency Fill Line

Ajinomoto Bio-Pharma Services recently announce the US FDA has approved the company’s high potency vial line to manufacture a commercial product…..

  WHITEPAPERS & WEBINARS

WHITEPAPER - Unique Manufacturing Challenges Associated With Sterile Eye Ointments

WHITEPAPER - Unique Manufacturing Challenges Associated With Sterile Eye Ointments

The manufacture of ophthalmic ointments is much more complex than the production of ocular liquid therapies and presents several unique challenges. It is essential for drug developers to choose outsourcing partners with extensive manufacturing experience with these specialized capabilities in …

WHITEPAPER - Improve Process Economics & Enable High Protein Concentrations

WHITEPAPER - Improve Process Economics & Enable High Protein Concentrations

This white paper evaluates the effect of the excipients in the Viscosity Reduction Platform on ultrafiltration processes used to produce a highly concentrated formulation of a monoclonal antibody (mAb). Two filtration methods are demonstrated in this work.

Click here to …

WHITEPAPER - Purity is Paramount: Assessing N-Oxide Impurities in Lipids Used in Lipid Nanoparticle Delivery Systems

WHITEPAPER - Purity is Paramount: Assessing N-Oxide Impurities in Lipids Used in Lipid Nanoparticle Delivery Systems

By: Sabrina Metze, PhD, Ulrich Klöckner, PhD, Lars Geiger, PhD, Justin Schieven, PhD, and Thomas Böhmer*

Summary

The quality of lipids in a lipid nanoparticle assembly is critically important to the functionality of mRNA-based therapeutics. Packer et al. have identified …

WHITEPAPER - Infographic-Zydis® Orally Disintegrating Tablet (ODT) vs. Standard Tablets (ST)

WHITEPAPER - Infographic-Zydis® Orally Disintegrating Tablet (ODT) vs. Standard Tablets (ST)

Abstract: Catalent’s proprietary Zydis® ODT platform is backed by a large number of clinical studies. This infographic provides a high level summary of studies comparing Zydis ODT against traditional oral tablets. Factors addressed include bioavailability, safety, side effects, speed/pharmacokinetics, variability, …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

May 3 – Nasal Delivery
May 10 – Capsules